Temozolomide (TMZ) CAS 85622-93-1 Assay 99.0%~101.0% API Factory High Purity
Nyete Temozolomide na ihe etiti emetụtara:
Temozolomide CAS: 85622-93-1
4 (5)-Amino-5 (4) -Imidazolecarboxamide CAS: 360-97-4
5 (4)-Amino-4 (5) -Imidazolecarboxamide Hydrochloride CAS: 72-40-2
Aha Chemical | Temozolomide |
Ụdị okwu | 3,4-Dihydro-3-Methyl-4-Oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-Carboxamide |
Nọmba CAS | 85622-93-1 |
Nọmba CAT | RF-API29 |
Ọnọdụ Ahịa | N'ọkwa, Mpụta Ihe ruru Tọn |
Usoro ihe omimi | C6H6N6O2 |
Ibu molekụla | 194.15 |
Ebe Na-agbaze | 212 ℃ Dec. |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Ntụ ntụ pink na-acha ọcha |
njirimara | Site na IR, HPLC |
Ihe mgbaze fọdụrụnụ | Dimethyl sulfoxide ≤0.50% |
Ihe ndị emetụtara | |
AIC adịghị ọcha | ≤0.10% |
Otu adịghị ọcha | ≤0.10% |
Zuru ike na-adịghị ọcha | ≤0.30% |
Mgbakọta adịghị ọcha | ≤0.30% |
Ọla dị arọ | ≤10ppm |
Ọnwụ na ihicha | ≤0.50% |
Ihe fọdụrụ na mgbanye | ≤0.10% |
Nyocha | 99.0% ~ 101.0% (HPLC na ntọala a mịrị amị) |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ojiji | Ngwakọta ọgwụ na-arụ ọrụ (API) |
ngwugwu: Kalama, Aluminom foil bag, kaadiboodu drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ọkụ, mmiri mmiri na ụmụ ahụhụ.
![1](https://a395.goodao.net/uploads/15.jpg)
![](https://a395.goodao.net/uploads/23.jpg)
Shanghai Ruifu Chemical Co., Ltd bụ onye na-emepụta ihe na onye na-ebubata Temozolomide (CAS: 85622-93-1) nke nwere oke mma.Temozolomide (TMZ) bụ onye na-ahụ maka alkylating ọnụ nke ejiri na-agwọ Glioblastoma Multiforme (GBM) na Astrocytomas, Metastatic Melanoma.
Temozolomide bụ nke mbụ dị irè nke ọnụ na-ewere imidazole na ọgwụ anticancer nke klas tetrazine bụ nke ọgbọ nke abụọ nke onye na-ahụ maka alkylating nwere ọrụ antitumor na-enweghị ọrụ imeju metabolic mgbe nchịkwa ọnụ gasịrị.A na-akọwa ya site na ịbanye ngwa ngwa site na mgbochi ụbụrụ nke ọbara, ezigbo ndidi na ejighị ya na ọgwụ ndị ọzọ na-egbu egbu, yana inwe mmetụta synergistic na radiotherapy nke kwesịrị ekwesị maka ịgwọ nlọghachi azụ glioma dị njọ mgbe ọgwụgwọ nkịtị dị ka glioblastoma multiforme etuto ma ọ bụ astrocytoma degenerative.Ọ bụ akara nke mbụ maka ọgwụgwọ nke melanoma metastatic.
Ndị Cancer Research UK Group bụ nke mbụ rụpụtara Temozolomide, wee bufee ya na ụlọ ọrụ Schering-Plough (United States) maka mmepe.Ọ nwere usoro kemịkalụ ọhụụ ma bụrụ nke ihe nrụpụta anọ-imidazole.N'afọ 1999, akwadoro ya ịbanye n'ahịa na EU na US ebe ihe ngosi ikike na United States bụ maka ọgwụgwọ nke abụọ nke glioblastoma multiforme na degenerative star gliomas na ihe ngosi akwadoro nke EU bụ maka ịgwọ glioblastoma multiforme na-etolite ma ọ bụ na-alọghachi azụ. nke etinyelarị usoro ọgwụgwọ ọdịnala.Ịdị irè nke temozolomide n'ịgwọ glioblastoma multiforme enwetawo amara na Europe.